Clinical Trial Update: Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating SYNC-T immunotherapy for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• SYNC-T

Snippet

Sponsor: Williams Cancer Foundation | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: COMPLETED